Biocon Chairman Kiran Mazumdar Shaw tests positive for COVID-19

She has received several get-well-soon messages after she posted the tweet.

However, many other users have sarcastically hit hard on her for extensively vouching for the efficacy of its psoriasis drug- Itolizumab for treating Covid-19 patients, in order to enable the national Covid-19 task force to reconsider its decision on inclusion of Itolizumab in the clinical management protocol.

Also Read: Covid-19 Vaccine: Draw Up Immunization Strategy Now Itself, Says Biocon Chief Kiran Mazumdar-Shaw

Ironically people have been raising brows to ask if Shaw herself would come forward to test the vaccine and tweeted;

Medical Dialogues team had earlier reported that in a major controversy, the exemption of biotechnology major Biocon from conducting Phase 3 trials of its psoriasis drug Itolizumab, for its use in moderate to severe COVID-19 patients had raised many eyebrows.

On July 10, the Drugs Controller General of India (DCGI) approved the biologic drug under emergency use in India for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 in India. The drug's approval was based on the results of phase 2 clinical trials involving 30 patients at four hospitals in New Delhi and Mumbai.

Also Read: CONTROVERSY: DCGI Exempts Biocon From Phase 3 Trial Of COVID Drug Itolizumab, ICMR Sees Red